Press release
Diabetes Drugs Market is expected to reach US$ 178.01 Billion by 2033, GLP-1 segment holds 22.7% market revenue, North America Led 35% Share of global Market
Diabetes Drugs market
Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/diabetes-drugs-market?pratik
The growth of the global diabetes drugs market is being strongly driven by the escalating prevalence of diabetes worldwide and the rising demand for effective and accessible treatment options. According to the International Diabetes Federation (IDF), an estimated 537 million adults were living with diabetes in 2021, and this number is projected to surge to 783 million by 2045, highlighting a significant and expanding patient base. This rising diabetes cases are significantly driving the diabetes drugs market by expanding the global patient pool and increasing long-term treatment demand
United States: Key Industry Developments
✅ February 2025 - The Merilog rapid-acting insulin biosimilar (insulin-aspart-szjj) was approved by U.S. Food and Drug Administration (FDA), offering a more affordable and accessible alternative to Novolog for mealtime glucose control.
✅ January 2025 - Ozempic (semaglutide) gained FDA approval for reducing the risk of kidney disease progression and cardiovascular events in adults with type 2 diabetes and chronic kidney disease (CKD), expanding its therapeutic value beyond glycemic control.
✅ 2025 (H1) - Market reports indicate North America continues to hold a dominant share ( 35 %) of the global diabetes drugs market, driven by high drug adoption rates, regulatory support, and advanced healthcare infrastructure.
Europe: Key Industry Developments
✅ July 2025: The European market is seeing rapid uptake of oral GLP-1 and SGLT-2 class drugs, driven by their added cardiovascular and renal benefits beyond just glycemic control. The European Union (EU) is also moving towards integrating digital health solutions, such as e-prescriptions, which is accelerating the shift to online dispensing of medications.
✅ June 2025: The unprecedented demand for GLP-1 drugs for both diabetes and obesity indications across Europe has outpaced manufacturing capacity, leading to periodic shortages and prescription caps.
Recent Merges & acquisition
→ Novo Nordisk acquired Akero Therapeutics for $5.2 billion on an unspecified date in 2025, targeting MASH and metabolic diseases to complement GLP-1 therapies like Wegovy for early-stage patients and efruxifermin for advanced liver damage.
→ GSK acquired efimosfermin alfa from Boston Pharmaceuticals on July 7, 2025, for $1.2 billion upfront plus up to $800 million in milestones, advancing Phase 3 trials for steatotic liver disease including MASH with cirrhosis.
→ Mallinckrodt Pharmaceuticals merged with Endo, Inc. in August 2025 for $6.7 billion, combining specialties in autoimmune and rare diseases with diabetes-focused therapeutics from MannKind financing.
Why Purchase the Report?
→ Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
→ Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
→ Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
→ Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
→ Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
→ Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
→ Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=diabetes-drugs-market?pratik ((Purchase 2 or more Repots and get 50% Discount)
Market Segmentation-
Segmentation by Drug Class
→ GLP-1 Receptor Agonists: These are injectable or oral medications that mimic the GLP-1 hormone to stimulate insulin release, slow gastric emptying, and reduce appetite, primarily used for type 2 diabetes management. This segment dominated with about 22.7% market share in 2024 and continues to lead due to high demand for innovative therapies and ongoing R&D for new drugs.
→ Insulin: Essential hormone replacement therapy for type 1 diabetes and advanced type 2 cases, available in various forms like long-acting and rapid-acting analogs for glycemic control. It holds a significant portion, reinforced by widespread use and biosimilar availability, though exact 2025 share data varies by report.
→ SGLT2 Inhibitors: Oral drugs that promote glucose excretion through urine, offering cardiovascular and renal benefits alongside blood sugar control. Identified as an emerging segment with strong growth potential due to expanding indications.
→ DPP-4 Inhibitors: Oral agents that inhibit the DPP-4 enzyme to prolong incretin effects, enhancing insulin secretion and reducing glucagon. They rank as a key type alongside insulin, driven by efficacy in type 2 diabetes.
→ Others: Includes biguanides like metformin (first-line oral therapy), sulfonylureas, alpha-glucosidase inhibitors, and more, covering a broad range of older and adjunct treatments. This category supports the market but trails newer classes in share.
Segmentation by Diabetes Type
→ Type 2 Diabetes: The most prevalent form, linked to insulin resistance and lifestyle factors like obesity, managed with oral drugs, injectables, and lifestyle interventions. It accounts for the largest market share due to higher global incidence and chronic treatment needs.
→ Type 1 Diabetes: Autoimmune condition requiring lifelong insulin therapy from diagnosis, often in younger patients. This segment holds about 4.4% market share in 2025, growing with rising diagnoses in developing regions.
Regional insights:-
→ North America
North America dominated the diabetes drugs market in 2024 with a valuation of USD 44.12 billion, representing the largest regional share due to high diabetes prevalence in the U.S., advanced healthcare infrastructure, and favorable reimbursement policies. The U.S. alone held the highest share within the region and is projected to reach USD 46.78 billion in 2025.
→ Europe
Europe secured the second-largest market share in 2024 and is expected to reach USD 24.86 billion in 2025, growing at a CAGR of 12.62%. Key drivers include rising diabetes drug launches, key player penetration, and increased treatment awareness. The region benefits from strong healthcare systems across major countries like Germany and the UK.
→ Asia Pacific
Asia Pacific is projected as the third-largest market at USD 18.25 billion in 2025, fueled by high diabetes incidence in China and India. China's market is estimated at USD 7.85 billion, Japan at USD 5.50 billion, and India at USD 1.33 billion in 2025. The region shows the fastest growth potential with a 5.3% CAGR from 2025-2030 due to urbanization and expanded insurance.
Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/diabetes-drugs-market?pratik
Competitive Landscape:-
Eli Lilly and Company, Novo Nordisk, Merck & Co., Boehringer Ingelheim, Sanofi, AstraZeneca, Takeda, and Novartis AG.Medtronic plc
→ Novo Nordisk holds the dominant position with approximately 34% global market share as of 2023-2025, fueled by blockbuster GLP-1 drugs like Ozempic, Rybelsus, and Victoza, which generated over DKK 149 billion in 2024 sales for type 2 diabetes treatments alone.
→ Eli Lilly ranks second, competing aggressively with GLP-1 products like Mounjaro, contributing to the top five players collectively holding over 62% of the market, though exact shares vary by report.
→ Sanofi is the third key player, known for insulin and other diabetes therapies, consistently listed among leaders alongside Novo Nordisk and Eli Lilly in major market analyses.
Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes Drugs Market is expected to reach US$ 178.01 Billion by 2033, GLP-1 segment holds 22.7% market revenue, North America Led 35% Share of global Market here
News-ID: 4298367 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Critical Minerals Market to Reach US$586.63 Billion by 2032, Growing at 7.53% CA …
Leander, Texas and Tokyo, Japan - Dec 03, 2025
According to DataM Intelligence, the global critical minerals market reached US$328.19 billion in 2024 and is expected to reach US$586.63 billion by 2032, growing with a CAGR of 7.53% during the forecast period 2025-2032. This substantial growth is propelled by the global energy transition, explosive demand for electric vehicles and renewable energy infrastructure, national security concerns over supply chain resilience, advancements in…
Software Defined Vehicle Market Surges at 22.15% CAGR Through 2032, Driven by As …
The Global Software Defined Vehicle (SDV) Market reached US$ 298.36 billion in 2024 and is projected to surge to US$ 1,478.72 billion by 2032, expanding at a remarkable CAGR of 22.15% during 2025-2032. SDVs are transforming the automotive landscape as vehicles shift from hardware-dependent architectures to fully software-centric systems. This evolution is being accelerated by rapid integration of AI, ML, over-the-air (OTA) updates, centralized computing, and advanced sensor fusion, enabling…
Anti-Inflammatory Drugs Market to Reach US$198.92 Billion by 2031, Growing at 8. …
Leander, Texas and Tokyo, Japan - Dec 03, 2025
According to DataM Intelligence, the global anti-inflammatory drugs market reached US$102.72 billion in 2023 and is expected to reach US$198.92 billion by 2031, growing at a CAGR of 8.7% during the forecast period 2024-2031. This robust growth is propelled by the rising global burden of chronic inflammatory diseases, increasing geriatric population, growing adoption of biologic therapies, advancements in targeted drug…
Sustainable Aviation Fuel Market Set for Explosive Growth to USD 4,841.5 Million …
The Sustainable Aviation Fuel Market reached USD 586.4 million in 2024 and is expected to reach USD 4,841.5 million by 2031, growing with a CAGR of 35.2% during the forecast period 2024-2031.
This robust growth is driven by technological advances in fuel production, increasing airline commitments to low-carbon fuels, and rising demand from commercial and military aviation sectors amid global decarbonization efforts. Government mandates, partnerships between airlines and producers, and investments…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
